Focused On-demand Library for Interleukin-23 receptor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5VWK5

UPID:

IL23R_HUMAN

Alternative names:

Alternative UPACC:

Q5VWK5; C9JGX4; Q4VGP1; Q4VGP2; Q4VGP3; Q4VGP4; Q4VGP5; Q4VGP6; Q5VWK7; Q8IW84; Q8NFQ9; Q96AS1

Background:

The Interleukin-23 receptor, encoded by the gene with accession number Q5VWK5, plays a pivotal role in the immune system. It forms a complex with IL12RB1 to bind IL23, initiating the Jak-Stat signaling cascade. This process is crucial for the stimulation of T-cells, NK cells, and certain macrophage/myeloid cells, contributing to both innate and adaptive immunity. Its involvement in the body's acute response to peripheral tissue infections underscores its significance.

Therapeutic significance:

Given its central role in mediating immune responses, the Interleukin-23 receptor is implicated in Inflammatory bowel disease 17, encompassing Crohn's disease and ulcerative colitis. These conditions are characterized by chronic inflammation of the gastrointestinal tract. Understanding the receptor's function could lead to novel therapeutic strategies targeting these autoimmune inflammatory diseases, potentially offering new hope for patients.